SCHEMBL5457434

SCHEMBL5457434

CCCCNc1cccc2c(-c3ccnc(N4CCN(CCOC)CC4)n3)c(-c3ccc(F)cc3)nn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.41
CSNK1D P48730 1/20 0.40
CSNK1E P49674 1/20 0.40
ACVR1 Q04771 8/20 0.38
MAPK14 Q16539 2/20 0.37
HTR1A P08908 1/20 0.37
DRD2 P14416 1/20 0.37
DRD1 P21728 1/20 0.37
HTR2A P28223 1/20 0.37
DRD3 P35462 1/20 0.37
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460116 0.91 SCN9A (0.40) ACHECSNK1DCSNK1EMAPK14HTR1A
SCHEMBL5453336 0.88 MAPK14 (0.40) MAPK14
SCHEMBL5464501 0.86 ALDH1A1 (0.40) CSNK1DMAPK14MAPK13MAPK12MAPK11
SCHEMBL5457474 0.83 GSK3B (0.49) CSNK1DMAPK14MAPK13MAPK12MAPK11
SCHEMBL5457545 0.83 MAPK14 (0.46) MAPK14MAPK13MAPK12MAPK11KDM4E
SCHEMBL5464065 0.81 DYRK1A (0.35) ACHEMAPK14ALDH1A1MAPTSMN1; SMN2
SCHEMBL14339988 0.80 MAPK14 (0.48) MAPK14
SCHEMBL5457524 0.80 GSK3B (0.46) MAPK14
SCHEMBL5455146 0.79 MAPK14 (0.43) MAPK14
SCHEMBL5464011 0.79 MKNK1 (0.47) CSNK1DMAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP claimed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287721-A1 Pyrazolopyridinyl pyridine CYP3A5, CYP2C19, CYP3A4 ACHE 2221/4885CSNK1D 411/4885CSNK1E 746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.